Cargando…

Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives

Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a set of clinically chronic, relapsing gastrointestinal inflammatory disease and lacks of an absolute cure. Although the precise etiology is unknown, developments in high-throughput microbial genomic se...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengfan, Yang, Lijiao, Mu, Chenlu, Sun, Yue, Gu, Yu, Chen, Danfeng, Liu, Tianyu, Cao, Hailong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125655/
https://www.ncbi.nlm.nih.gov/pubmed/35664229
http://dx.doi.org/10.1016/j.csbj.2022.03.038
_version_ 1784711984191635456
author Li, Mengfan
Yang, Lijiao
Mu, Chenlu
Sun, Yue
Gu, Yu
Chen, Danfeng
Liu, Tianyu
Cao, Hailong
author_facet Li, Mengfan
Yang, Lijiao
Mu, Chenlu
Sun, Yue
Gu, Yu
Chen, Danfeng
Liu, Tianyu
Cao, Hailong
author_sort Li, Mengfan
collection PubMed
description Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a set of clinically chronic, relapsing gastrointestinal inflammatory disease and lacks of an absolute cure. Although the precise etiology is unknown, developments in high-throughput microbial genomic sequencing significantly illuminate the changes in the intestinal microbial structure and functions in patients with IBD. The application of microbial metabolomics suggests that the microbiota can influence IBD pathogenesis by producing metabolites, which are implicated as crucial mediators of host-microbial crosstalk. This review aims to elaborate the current knowledge of perturbations of the microbiome–metabolome interface in IBD with description of altered composition and metabolite profiles of gut microbiota. We emphasized and elaborated recent findings of several potentially protective metabolite classes in IBD, including fatty acids, amino acids and derivatives and bile acids. This article will facilitate a deeper understanding of the new therapeutic approach for IBD by applying metabolome-based adjunctive treatment.
format Online
Article
Text
id pubmed-9125655
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Research Network of Computational and Structural Biotechnology
record_format MEDLINE/PubMed
spelling pubmed-91256552022-06-04 Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives Li, Mengfan Yang, Lijiao Mu, Chenlu Sun, Yue Gu, Yu Chen, Danfeng Liu, Tianyu Cao, Hailong Comput Struct Biotechnol J Mini Review Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a set of clinically chronic, relapsing gastrointestinal inflammatory disease and lacks of an absolute cure. Although the precise etiology is unknown, developments in high-throughput microbial genomic sequencing significantly illuminate the changes in the intestinal microbial structure and functions in patients with IBD. The application of microbial metabolomics suggests that the microbiota can influence IBD pathogenesis by producing metabolites, which are implicated as crucial mediators of host-microbial crosstalk. This review aims to elaborate the current knowledge of perturbations of the microbiome–metabolome interface in IBD with description of altered composition and metabolite profiles of gut microbiota. We emphasized and elaborated recent findings of several potentially protective metabolite classes in IBD, including fatty acids, amino acids and derivatives and bile acids. This article will facilitate a deeper understanding of the new therapeutic approach for IBD by applying metabolome-based adjunctive treatment. Research Network of Computational and Structural Biotechnology 2022-04-04 /pmc/articles/PMC9125655/ /pubmed/35664229 http://dx.doi.org/10.1016/j.csbj.2022.03.038 Text en © 2022 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Mini Review
Li, Mengfan
Yang, Lijiao
Mu, Chenlu
Sun, Yue
Gu, Yu
Chen, Danfeng
Liu, Tianyu
Cao, Hailong
Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives
title Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives
title_full Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives
title_fullStr Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives
title_full_unstemmed Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives
title_short Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives
title_sort gut microbial metabolome in inflammatory bowel disease: from association to therapeutic perspectives
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125655/
https://www.ncbi.nlm.nih.gov/pubmed/35664229
http://dx.doi.org/10.1016/j.csbj.2022.03.038
work_keys_str_mv AT limengfan gutmicrobialmetabolomeininflammatoryboweldiseasefromassociationtotherapeuticperspectives
AT yanglijiao gutmicrobialmetabolomeininflammatoryboweldiseasefromassociationtotherapeuticperspectives
AT muchenlu gutmicrobialmetabolomeininflammatoryboweldiseasefromassociationtotherapeuticperspectives
AT sunyue gutmicrobialmetabolomeininflammatoryboweldiseasefromassociationtotherapeuticperspectives
AT guyu gutmicrobialmetabolomeininflammatoryboweldiseasefromassociationtotherapeuticperspectives
AT chendanfeng gutmicrobialmetabolomeininflammatoryboweldiseasefromassociationtotherapeuticperspectives
AT liutianyu gutmicrobialmetabolomeininflammatoryboweldiseasefromassociationtotherapeuticperspectives
AT caohailong gutmicrobialmetabolomeininflammatoryboweldiseasefromassociationtotherapeuticperspectives